Nanobiotix: upbeat after half-year results

(CercleFinance.com) - Nanobiotix climbs over 6% following the publication of a net loss attributable to ordinary shareholders of 21.
9 million euros for the first half of 2024, down from 28.1 million euros for the same period in 2023.

Total sales and other operating income rose from 3.3 to 9.3 million euros year-on-year, mainly thanks to the supply of products and the provision of services under the agreement with Janssen Pharmaceutica.

Nanobiotix expects that its cash and cash equivalents of €66.3 million at the end of June 2024 are now sufficient to finance its operating expenses until the fourth quarter of 2025, rather than the third quarter of 2025.

Copyright (c) 2024 CercleFinance.com. All rights reserved.